Today's Rundown Roivant lines up $3B upfront in Sumitomo Dainippon deal Zealand CSO steps up as chief of French biotech Zafgen hangs 'for sale' sign as chances of imminent recovery fade Opthea’s Lucentis/VEGF ‘trap’ combo outshines Lucentis alone in wet AMD Applying 'rock-paper-scissors' gene circuits to cancer therapy EuroBiotech Report—Achilles raises $100M, MGB round, Genfit CEO change and AstraZeneca FiercePharmaAsia—Biocon, Mylan’s Lantus copy CRL; CStone CEO pay; Novartis’ site sale Chutes & Ladders—Bausch Health's Salix loses McKenna to Prometheus Featured Story | | | Friday, September 6, 2019 Sumitomo Dainippon is set to pay $3 billion upfront to buy Roivant’s stake in five of its Vant startups. The deal could provide Dainippon with a series of new product launches to offset the loss of patent protection on bipolar depression drug Latuda. |
|
|---|
|
Top Stories Friday, September 6, 2019 At the end of July, Zealand Pharma’s chief scientific officer Andrew Parker, Ph.D., hit the exit, off to an unknown biotech. Today, we know where he landed: as CEO of Step Pharma. Thursday, September 5, 2019 Zafgen has begun looking for someone to rescue it from its sticky predicament. The biotech put out the call for a strategic alternatives after preliminary data from an animal study suggested it is unlikely to get ZGN-1061 out from under a FDA clinical in the near term. Friday, September 6, 2019 Opthea tested two doses of its drug, OPT-302, in combination with Lucentis, finding that the combo bested Lucentis alone at improving vision and reducing scarring in the retina. The Australian company is now gearing up for a phase 3 study. Thursday, September 5, 2019 By cycling through three strains of bacteria, bioengineers at the University of California San Diego developed a “rock-paper-scissors” method to prolong the function of gene circuits that can be used to produce and deliver cancer drugs. Thursday, September 5, 2019 In this week's EuroBiotech Report, Achilles raises $100 million, MGB tops up cash reserves and Genfit unveils CEO transition. Friday, September 6, 2019 Mylan's Lantus copy was rejected by the FDA again, thanks to partner Biocon's manufacturing shortfalls. Chinese biotech CStone's CEO made nearly $20 million in pay last year, putting him on par with Merck & Co.'s CEO. Novartis will sell its Suzhou, China plant for $111 million. And more. Friday, September 6, 2019 Bausch Health's Salix loses president Mark McKenna; Bayer nabs dealmaker Marianne De Backer from J&J; AltaSciences nabs Charles River exec Lynne LeSauteur. | This week's sponsor is ExL Events. | | | |
Enrollment Showcase | | | October 23-25, 2019 | Chicago, IL | Presented by Biotech Primer BioImmersion: Biotech for the Non-Scientist is a three-day, in-depth course that delves into the scientific details on a broad number of biotechnology topics. Register today! |
|
|---|
|
Resources Sponsored by: Patheon, by Thermo Fisher Scientific Avoid potential risks to the patient as well as costly interruptions during development. Sponsored by: Vineti Developing a cell therapy, gene therapy, or personalized cancer vaccine? Modern data management makes a critical difference in operational and regulatory outcomes. This whitepaper will help your team leverage the latest data strategies for success. Sponsored by: AlphaSense AI-powered research tools are making it easier to source confident healthcare market intelligence with accuracy and efficiency -- download now to learn more about improving your competitive research strategy. Sponsored by: Elemental Machines Your lab is talking to you, are you listening? Sponsored by: Frenova Want to be sure your renal research protocol design is fit for the real world? Sponsored by: Recro Gainesville Vetting CDMOs but unsure what to look for in prospective partners’ multiproduct facilities? Sponsored by: Accenture Clinical trials are one of the pharma industry’s most painful and costly processes. Read how technology could transform the trial process from nine years to a matter of hours. Sponsored by: Baxter BioPharma Solutions Check out Baxter BioPharma Solutions’ whitepaper to learn considerations and options for developing a product in a prefilled syringe. Sponsored by: Alexander Group From sales headcount and budgets to new product launches and saying “yes” to millennials, hear the top 7 topics that are trending in sales compensation. Sponsored by: Wesco Pharmaceutical Solutions and WBR Insights The regulations and managing processes for hazardous, controlled and rare chemicals and biologics necessary for drug discovery are a huge distraction for R&D labs. Learn from the perspectives of industry executives the pain points and improvements they want in their processes for chemicals and biologics in pharmaceuticals R&D. Sponsored by: Kinaxis Download this life sciences industry spotlight to discover how concurrent planning can help you overcome complex supply chain challenges to drive down costs and improve efficiency. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. U.S. Healthcare Compliance Certificate Program October 14-17, 2019 | Newark, New Jersey European Healthcare Compliance Certificate Program October 21-25, 2019 | Paris, France BioBasics: Biotech For The Non-Scientist Oct 22-23, 2019 | San Diego, CA BioImmersion: Biotech for the Non-Scientist October 23-25, 2019 | Chicago, IL 4th FierceBiotech Drug Development Forum October 28-29, 2019 | Boston, MA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register NOW and start Pre-Boot Camp Preparation! | 